Dapsone is a Small Molecule owned by AbbVie, and is involved in 22 clinical trials, which were completed.
Dapsone inhibits dihydropteroate synthase (DHPS), an enzyme important in folate synthesis, resulting in a depletion of the folate pool and a reduction in the amount of thymidylate available for DNA synthesis. It exerts its anti-inflammatory activity by interfering with the activation and oxidative damage of myeloperoxidase in neutrophils and inhibits the integrin-mediated adherence and chemotaxis of neutrophils.
The revenue for Dapsone is expected to reach a total of $62m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Dapsone NPV Report.
Dapsone (Aczone) is a synthetic derivative of diamino-sulfone with anti-inflammatory and anti-bacterial properties. It is formulated as gel for topical application. Dapsone is indicated for the treatment of acne vulgaris.
Dapsone (Artisone) was under development for the treatment of acne, atopic dermatitis, intense itch often associated with healing of severe burn wounds and rosacea. It is formulated as tablets for oral route of administration and as gel for topical application.
Almirall is a specialty pharmaceutical company that researches, develops, manufactures, and commercializes proprietary medicines and licensed products. The company’s major area of focus is dermatology covering psoriasis, eczema, acne, and other skin infections. It also develops products for autoimmune diseases including rheumatoid arthritis and multiple sclerosis; and gastrointestinal diseases including irritable bowel syndrome with constipation. The company also works together with small and medium-sized companies and healthcare professionals to develop medical solutions and provide them to patients. It operates through affiliates in Europe and Central America and has R&D centers in Spain and Germany. Almirall is headquartered in Barcelona, Spain.
The company reported revenues of (Euro) EUR827.2 million for the fiscal year ended December 2021 (FY2021), an increase of 2.4% over FY2020. In FY2021, the company’s operating margin was 0.7%, compared to an operating margin of 11.4% in FY2020. The net loss of the company was EUR40.9 million in FY2021, compared to a net profit of EUR74.3 million in FY2020. The company reported revenues of EUR197.2 million for the third quarter ended September 2022, a decrease of 54.8% over the previous quarter.
Quick View – Dapsone
|Highest Development Stage|